Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests
The phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. Kidney graft function stabilized after the first month of treatment and remained higher in tegoprubart-treated patients than in…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Reprogramming tumor microenvironment could improve prospects for treatment of pancreatic cancer
United Kingdom
-
US–Mexico border counties face high kidney disease–related mortality and low nephrologist availability
United Kingdom
-
Standard kidney function tests underestimate chronic kidney disease in people with cancer
United Kingdom
-
Melanoma vaccine reduces death or cancer recurrence by 42%
United Kingdom
-
5 great cardio workouts you can do at home
United Kingdom
-
Online resources and coaching helped people seek genetic testing for cancer
United Kingdom
-
Study identifies potential new treatment targets for the most common type of bowel cancer
United Kingdom
-
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
United Kingdom